AWH vs. ICCC, OCX, ABIO, CDIO, TRIB, BMRA, VNRX, TKNO, GBS, and RPID
Should you be buying Aspira Women's Health stock or one of its competitors? The main competitors of Aspira Women's Health include ImmuCell (ICCC), OncoCyte (OCX), ARCA biopharma (ABIO), Cardio Diagnostics (CDIO), Trinity Biotech (TRIB), Biomerica (BMRA), VolitionRx (VNRX), Alpha Teknova (TKNO), GBS (GBS), and Rapid Micro Biosystems (RPID). These companies are all part of the "medical" sector.
Aspira Women's Health (NASDAQ:AWH) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, community ranking, dividends and analyst recommendations.
In the previous week, Aspira Women's Health had 4 more articles in the media than ImmuCell. MarketBeat recorded 12 mentions for Aspira Women's Health and 8 mentions for ImmuCell. ImmuCell's average media sentiment score of 0.45 beat Aspira Women's Health's score of 0.40 indicating that ImmuCell is being referred to more favorably in the news media.
ImmuCell has higher revenue and earnings than Aspira Women's Health. ImmuCell is trading at a lower price-to-earnings ratio than Aspira Women's Health, indicating that it is currently the more affordable of the two stocks.
ImmuCell received 108 more outperform votes than Aspira Women's Health when rated by MarketBeat users. Likewise, 73.33% of users gave ImmuCell an outperform vote while only 28.26% of users gave Aspira Women's Health an outperform vote.
ImmuCell has a net margin of -33.05% compared to Aspira Women's Health's net margin of -176.74%. ImmuCell's return on equity of -21.79% beat Aspira Women's Health's return on equity.
Aspira Women's Health currently has a consensus target price of $4.45, indicating a potential upside of 58.93%. Given Aspira Women's Health's higher probable upside, equities analysts clearly believe Aspira Women's Health is more favorable than ImmuCell.
Aspira Women's Health has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, ImmuCell has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.
12.2% of Aspira Women's Health shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 4.3% of Aspira Women's Health shares are held by insiders. Comparatively, 6.3% of ImmuCell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
ImmuCell beats Aspira Women's Health on 11 of the 17 factors compared between the two stocks.
Get Aspira Women's Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for AWH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AWH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aspira Women's Health Competitors List
Related Companies and Tools
